Future studies should focus on whether silencing of STAT3 expression using STAT3 shRNA or its inhibitor such as non-receptor tyrosine kinase is useful as a novel adjuvant therapy to chemotherapy for pancreatic cancer patients. This evidence concerns the gene STAT3 and pancreatic neoplasm.